Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 11, 2016 - Issue 10
Submit an article Journal homepage
2,561
Views
7
CrossRef citations to date
0
Altmetric
Editorial

Novel strategies for discovering inhibitors of Dengue and Zika fever

Huda MakhlufLa Jolla Institute for Allergy & Immunology, Center for Infectious Disease, La Jolla, CA, USA;Department of Mathematics and Natural Sciences, National University, La Jolla, CA, USACorrespondence[email protected]
,
Kenneth KimLa Jolla Institute for Allergy & Immunology, Center for Infectious Disease, La Jolla, CA, USA
&
Sujan ShrestaLa Jolla Institute for Allergy & Immunology, Center for Infectious Disease, La Jolla, CA, USA
Pages 921-923 | Received 22 Feb 2016, Accepted 08 Jul 2016, Published online: 21 Jul 2016

References

  • Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature Publishing Group. 2013;496:504–507. doi:10.1038/nature12060
  • Wyles D. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013;S 33- S 39. doi:10.1093/infdis/jis761.
  • De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33:307–320. doi:10.1016/j.ijantimicag.2008.10.010.
  • Plummer E, Buck MD, Sanchez M, et al. Dengue virus evolution under a host-targeted antiviral. J Virol. 2015;89:5592–5601. doi:10.1128/JVI.00028-15.
  • Pheng S, Wang Q, Noble CG, et al. Ten years of dengue drug discovery : progress and prospects. Antiviral Res. 2013;100:500–519. doi:10.1016/j.antiviral.2013.09.013
  • Watanabe S, Chan KW, Dow G, et al. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2 : the search for a window for potential therapeutic ef fi cacy. Antiviral Res. 2016;127:10–19. doi:10.1016/j.antiviral.2015.12.008
  • Warfield KL, Plummer E, Alonzi DS, et al. Influenza V. A novel iminosugar UV-12 with activity against the diverse Viruses influenza and dengue (Novel iminosugar antiviral for influenza and dengue). Viruses. 2015;7:2404–2427.
  • Heaton NS, Moshkina N, Fenouil R, et al. Targeting viral Proteostasis limits influenza virus, HIV, and dengue virus. Infection. 2016;44:46–58. doi:10.1007/s15010-015-0856-9.
  • Taguwa S, Maringer K, Li X, et al. Defining Hsp70 subnetworks in dengue virus replication reveals key vulnerability in flavivirus infection. Cell. 2015;163:1108–1123. doi:10.1016/j.cell.2015.10.046.
  • Pinto AK, Brien JD, Lam CK, et al. Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection. MBio. 2015;6:1–13. doi:10.1128/mBio.01316-15.
  • Suzuki Y, Chin W, Han QE, et al. Characterization of RyDEN (C19orf66) as an interferon-stimulated cellular inhibitor against dengue virus replication. PLoS Pathog. 2016;12:1–37. doi:10.1371/journal.ppat.1005357.
  • Tang WW, Grewal R, Shresta S. Influence of antibodies and T cells on dengue disease outcome : insights from interferon receptor-deficient mouse models. Curr Opin Virol. 2015;13:61–66. doi:10.1016/j.coviro.2015.04.007
  • Deligny C, De Bandt M, Dehlinger V, et al. Dengue fever in patients under biologics. J Clin Virol. 2014;61:442–443. doi:10.1016/j.jcv.2014.08.027.
  • National University Hospital, Singapore; Duke-NUS Graduate Medical School; Singapore General Hospital. Ketotifen as a treatment for vascular leakage during dengue fever (KETODEN). ClinicalTrials.gov [Internet] . Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 May 18]. Available from: http://clinicaltrials.gov/show/NCT02673840 NLM Identifier: NCT02673840
  • Burel JG, Apte SH, Doolan DL. Systems approaches towards molecular profiling of human immunity. Trends Immunol. 2016;37:53–67. doi:10.1016/j.it.2015.11.006

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.